These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33668879)

  • 1. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns.
    Wennmann M; Hielscher T; Kintzelé L; Menze BH; Langs G; Merz M; Sauer S; Kauczor HU; Schlemmer HP; Delorme S; Goldschmidt H; Weinhold N; Hillengass J; Weber MA
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria.
    Wennmann M; Hielscher T; Kintzelé L; Menze BH; Langs G; Merz M; Sauer S; Kauczor HU; Schlemmer HP; Delorme S; Goldschmidt H; Weinhold N; Hillengass J; Weber MA
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32906608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid simultaneous whole-body 2-[
    Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
    Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.
    Hillengass J; Fechtner K; Weber MA; Bäuerle T; Ayyaz S; Heiss C; Hielscher T; Moehler TM; Egerer G; Neben K; Ho AD; Kauczor HU; Delorme S; Goldschmidt H
    J Clin Oncol; 2010 Mar; 28(9):1606-10. PubMed ID: 20177023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of focal lesion characteristics in MRI which indicate presence of corresponding osteolytic lesion in CT in patients with multiple myeloma.
    Hildenbrand N; Klein A; Maier-Hein K; Wennmann M; Delorme S; Goldschmidt H; Hillengass J
    Bone; 2023 Oct; 175():116857. PubMed ID: 37487861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
    Merz M; Hielscher T; Wagner B; Sauer S; Shah S; Raab MS; Jauch A; Neben K; Hose D; Egerer G; Weber MA; Delorme S; Goldschmidt H; Hillengass J
    Leukemia; 2014 Sep; 28(9):1902-8. PubMed ID: 24535407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
    Zamagni E; Nanni C; Gay F; Pezzi A; Patriarca F; Bellò M; Rambaldi I; Tacchetti P; Hillengass J; Gamberi B; Pantani L; Magarotto V; Versari A; Offidani M; Zannetti B; Carobolante F; Balma M; Musto P; Rensi M; Mancuso K; Dimitrakopoulou-Strauss A; Chauviè S; Rocchi S; Fard N; Marzocchi G; Storto G; Ghedini P; Palumbo A; Fanti S; Cavo M
    Leukemia; 2016 Feb; 30(2):417-22. PubMed ID: 26490489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].
    Bhutani M; Landgren O
    Radiologe; 2014 Jun; 54(6):572, 574-81. PubMed ID: 24927659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Informativeness of whole-body diffusion-weighted magnetic resonance imaging and positron emission tomography with computed tomography in follicular lymphoma].
    Nesterova ES; Yatsyk GA; Lutsik NS; Kravchenko SK; Sudarikov AB; Krasil'nikova IV; Gemdzhian EG; Kovrigina AM
    Ter Arkh; 2020 Sep; 92(7):55-62. PubMed ID: 33346445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
    Walker R; Barlogie B; Haessler J; Tricot G; Anaissie E; Shaughnessy JD; Epstein J; van Hemert R; Erdem E; Hoering A; Crowley J; Ferris E; Hollmig K; van Rhee F; Zangari M; Pineda-Roman M; Mohiuddin A; Yaccoby S; Sawyer J; Angtuaco EJ
    J Clin Oncol; 2007 Mar; 25(9):1121-8. PubMed ID: 17296972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma.
    Jamet B; Bailly C; Carlier T; Touzeau C; Michaud AV; Bourgeois M; Moreau P; Bodet-Milin C; Kraeber-Bodere F
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
    Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J
    Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bone marrow infiltration in multiple myeloma using whole-body diffusion-weighted imaging and T1-weighted water-fat separation Dixon.
    Ji X; Huang W; Dong H; Shen Z; Zheng M; Zou D; Shen W; Xia S
    Quant Imaging Med Surg; 2021 Feb; 11(2):641-651. PubMed ID: 33532264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Diffuse Bone Marrow Infiltration Pattern in Monoclonal Plasma Cell Diseases by Quantitative Whole-body Magnetic Resonance Imaging.
    Sun M; Cheng J; Ren C; Zhang Y; Li Y; Wang L; Zhang S; Lin L
    Acad Radiol; 2022 Apr; 29(4):490-500. PubMed ID: 34362664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
    Messiou C; Porta N; Sharma B; Levine D; Koh DM; Boyd K; Pawlyn C; Riddell A; Downey K; Croft J; Morgan V; Stern S; Cheung B; Kyriakou C; Kaczmarek P; Winfield J; Blackledge M; Oyen WJG; Kaiser MF
    Radiol Imaging Cancer; 2021 Sep; 3(5):e210048. PubMed ID: 34559006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.
    Wennmann M; Kintzelé L; Piraud M; Menze BH; Hielscher T; Hofmanninger J; Wagner B; Kauczor HU; Merz M; Hillengass J; Langs G; Weber MA
    Oncotarget; 2018 May; 9(38):25254-25264. PubMed ID: 29861868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.
    Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Hillengass M; Wagner B; Hose D; Raab MS; Jauch A; Delorme S; Goldschmidt H; Weber MA; Hillengass J
    Eur Radiol; 2016 Nov; 26(11):3939-3948. PubMed ID: 26767378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.